Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares Core S&P 500 ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares Core S&P 500 ETF trades at $770.5 (market cap $896.34B). The key difference: iShares Core S&P 500 ETF is far larger — about 313.4× Dyne Therapeutics Inc. Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares Core S&P 500 ETF for 46 Days on average.
| DYN | IVV | |
|---|---|---|
Market Cap | $2.86B | $896.34B |
Volume | 3,341,579 | 3,965,666 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $782.58 |
52-Week Low | $14.60 | $634.93 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
IVV, tracking the S&P 500, trades at $781.42 with minimal daily change. Technical analysis shows a bullish trend with strong moving average support, though RSI indicates potential overbought conditions near-term. The ETF benefits from broad market exposure amid expectations of continued corporate profit growth, with S&P 500 earnings projected to rise 35% in 2026 according to 24/7 Wall Street on October 3, 2026.
Outlook remains positive given historical seasonal trends and strong institutional support, but risks include concentration in top holdings and potential profit growth deceleration. The ETF's low-cost structure and diversification provide stability, though market volatility and economic shifts could challenge near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
